RxSight, Inc 10-Q for FY2026 Q3
RxSight, Inc. (RXST)
10-Q
2026-11-03
For: 2026-09-30
View Original
Added on
November 03, 2026
About this 10-Q
RxSight, Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
RxSight quarterly revenue fell 19.0% to $24.6 million as lower LDD and LAL sales reflected increased competition. Its $50.0 million Alcon upfront payment became nonrefundable on October 28, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $24.59M
- down 19.0% from $30.34M a year earlier
- Net loss
- $16.22M
- compared with a net loss of $9.82M a year earlier
- Diluted EPS
- -$0.39
- compared with -$0.24 a year earlier